Hypertrophic Cardiomyopathy: Is a ‘Cure’ Coming . . . Or Is It Already Here?

Over its 60-year history, a consistent theme attached to hypertrophic cardiomyopathy (HCM) has been controversy concerning its prevalence, clinical course, and expectations for treatment benefit.1 Once regarded as rare and ominous, HCM is now recognized as a common genetic disease with worldwide distribution, broad spectrum, and clinical outcome transformed over the last several years by the introduction of management strategies that favorably alter its natural history and provide a high level of care for the vast majority of patients.